Hemopurifier - super Innovation
Seite 1 von 1 Neuester Beitrag: 24.04.21 23:52 | ||||
| Eröffnet am: | 19.03.14 23:11 | von: Iuben | Anzahl Beiträge: | 21 |
| Neuester Beitrag: | 24.04.21 23:52 | von: Franziskaquij. | Leser gesamt: | 7.874 |
| Forum: | Hot-Stocks | Leser heute: | 2 | |
| Bewertet mit: |  | |||
Da ich Biochemiker bin und in der Wissenschaft arbeite, hat mich diese Firma sehr interessiert. Ich forsche zwar nicht selbst an dem Thema Exosomen, aber meine Kollegen im Büro nebenan.
Da ich dank des Universitätszugang zu den Originalpublikationen/-studien zu diesem Thema Zugang habe, kann ich, nachdem ich mich durch einige Daten gewühlt habe, mit guten Gewissen sagen, das Konzept von „Aethlon Medical“ ist nicht nur solide, sondern wäre wirklich ein medizinischer Durchbruch.
Aber was genau macht die Firma:
Über das Produkt „Hemopurifier“ habe ich mich am meisten informiert:
Ursprünglich ist es nur dazu gedacht gewesen, durch Dialysen (Blutwasche) Patienten von Viren zu befreien. An sich schon ein ziemlich cooles Konzept. An unsere Uni arbeiten auch einige Forschergruppen an einem ähnlichen Verfahren. Allerdings scheint ihnen „Aethlon Medical“ einige Schritte (Meilen) voraus zu sein.
Jetzt hat sich aber offenbar ergeben, dass der „Hemopurifier“ auch Exosomen aus dem Blut filtert.
Ganz kurz: Exosomen sind kleine Blasen die unter bestimmten Umständen von Zellen abgeschnürt werden. Je nachdem was für Umstände vorliegen, sind diese Bläschen mit unterschiedlichen Biomolekülen beladen. Hat man die Bläschen/Exosomen erstmal mit dem „Hemopurifier“ aus dem Blut gewonnen, kann man untersuchen welche Biomoleküle in den Exosomen vorhanden sind.
Damit kann man beispielsweise auf verschiedene Krebsarten/Tumore oder Alzheimer rückschließen.
Generell kann man zusammenfassen, dass der „Hemopurifier“, sofern er sich bewährt ein unverzichtbares medizinisches Produkt für Diagnose und Behandlung von Krankheiten wird. Ich bin sehr gespannt!
Angehängte Grafik:
sc.png (verkleinert auf 60%)
sc.png (verkleinert auf 60%)
SAN DIEGO, Oct. 14, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany. The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone.
The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. The largest ebola virus epidemic in history is now spreading on a global basis with more than 4,000 deaths being reported by the WHO.
"We thank the physicians in Frankfurt for allowing us the opportunity to treat this advanced-stage patient," stated Aethlon founder and CEO, Jim Joyce. "Details related to the patient's response to therapy will be disclosed once hospital officials deem it appropriate to report an update on the condition of this individual."
In the care of ebola-infected individuals, the Hemopurifier targets two unmet medical needs: the rapid elimination of circulating ebola to inhibit continued progeny virus replication and the direct targeting of shed glycoproteins that overwhelm the host immune response. The device can be deployed for use within the global infrastructure of dialysis and CRRT machines already located in hospitals and clinics.
Aethlon further disclosed that it is preparing to initiate U.S. clinical studies of Hemopurifier therapy based on the United States Food and Drug Administration's (FDA) approval of an Investigational Device Exemption (IDE) that was previously submitted by the Company. The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).
To date, Hemopurifier therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals. These studies were conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India. In vitro validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of ebola virus were conducted by researchers at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and the United States Centers for Disease Control and Prevention (CDC).
Es ist schon super, dass das Vertrauen bei den Ärzten in Frankfurt für den Hemopurifier so groß ist, um ihn direkt einzusetzen.
Aber auch die ersten Studien zeigen ja, dass der Hemopurifier wirklich in der Lage ist die Viruslast im Körper zu vermindern. Dadurch gibt es sehr, sehr gute Chancen, dass sich der Hemopurifier als unterstützende Maßnahme bei der Behandlungen von Viruserkrankungen (HIV, Hepatitis, ...) durchsetzt; was einen Millionenmarkt darstellt.
Und das sind nur die Behandlungen von Viruserkrankungen. Wenn sich auch die positiven Auswirkungen bei der Krebstherapie bewahrheiten, hat Aethlon med hier ein kleines Wunderwerk erschaffen.
„Allerdings wird er noch einige Zeit benötigen, um sich vollständig zu erholen”, teilte der Vorstand des Krankenhauses mit. Der aus Uganda stammende Arzt wurde am 3. Oktober zur Behandlung nach Frankfurt gebracht, er hatte sich bei einem Einsatz in Sierra Leone mit dem tückischen Erreger infiziert. Zwischenzeitlich sei der Mann ernsthaft erkrankt gewesen und habe an Multiorganversagen gelitten, teilte das Krankenhaus mit.
um nur eine Quelle zu nennen.
Zusammengefasst: Der Patient wurde geheilt. Der Einsatz des Hemopurifiers während der Dialyse hat die Virenmenge im Körper des Patienten drastisch verringert. Es wurde auf 0.25 % der Menge vor der Dialyse gedrückt. Was eine Abnahme von 99.75% also fast 100% ser Virenmenge bedeutet.
Die geringe Menge die übrig blieb stellte dann kein Problem mehr für Immunsystem und antivirale Mittel dar.
Klar ist Ebola trotz des Ausbruches in Westafrika eher eine Nische. Aber Aethlon Medical hat bereits erfolgreiche Tests mit anderen Viren wie HIV und Hepatitis C durchgeführt. Krankheiten die weltweit von großer Bedeutung sind und wo der Hemopurifier eine mögliche Heilung darstellt.
Kurz gesagt: Der Hemopurifier hat seinen Fähigkeit unter Beweis gestellt und glänzend abgeschnitten.
Die Zukunft, in die Aethlon Medical steuert, ist spannend!
Quelle:
http://www.prnewswire.com/news-releases/...ited-states-283171891.html
http://time.com/3594971/the-25-best-inventions-of-2014/
Und der Kurs liegt schon fast bei 0.5 .
Aethlon Medical Announces First Hemopurifier® Shipment To Support the Treatment of Ebola in the United States
Alert
Aethlon Medical, Inc. (USOTC:AEMD)
Intraday Stock Chart
Today : Wednesday 26 November 2014
Click Here for more Aethlon Medical, Inc. Charts.
SAN DIEGO, Nov. 26, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today announced the first shipment of Hemopurifier® therapy as a candidate to treat future Ebola virus infections in the United States. The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.
Aethlon Hemopurifier.
Aethlon disclosed that four Hemopurifiers have been shipped to the Biocontainment Unit at the Nebraska Medical Center (NMC) in Omaha as a therapeutic option to be stockpiled for Ebola patients that may be treated at the NMC. Aethlon further disclosed that it has provided onsite training to NMC clinical personnel related to the implementation of Hemopurifier® therapy within the dialysis infrastructure already located at the center.
The Nebraska Biocontainment Unit was commissioned by The United States Centers for Disease Control (CDC) in 2005. It is a joint project involving Nebraska Medicine, Nebraska Health and Human Services, and the University of Nebraska Medical Center. It was designed to provide the first line of treatment for people affected by bioterrorism or extremely infectious naturally occurring diseases such as Ebola. It's the largest facility of its kind in the U.S. The NMC has treated three Ebola patients since the current outbreak. Additional details can be found online at: www.nebraskamed.com/biocontainment-unit
Aethlon previously reported the successful administration of Hemopurifier® therapy to a Ugandan doctor who was infected with Ebola virus and treated at the Frankfurt University Hospital in Germany. At the time Hemopurifier® therapy was administered, the doctor was unconscious and suffered from multiple organ failure. His viral load prior to the administration of a single 6.5-hour Hemopurifier® treatment was measured at 400,000 virus copies per milliliter of blood (copies/ml). Post-treatment viral load was measured at 1,000 copies/ml and never again rose above that level. Viral load became undetectable five days after therapy. The treatment was well tolerated with no adverse events reported. Additionally, a post-treatment elution protocol verified that 242 million Ebola viruses were captured within the Hemopurifier® during treatment. The doctor has since made a full recovery and has returned home to his family in Uganda.
In the United States, Hemopurifier® therapy is available to treat Ebola patients through FDA expanded access "emergency use" provisions to address life threatening circumstances for which an alternative therapy is not available. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans. Aethlon disclosed that it provided Hemopurifiers to the NMC on a humanitarian basis and therefore will not generate revenues as a result of its initial shipment.
Aethlon will soon begin the first U.S. clinical Hemopurifier® studies following the United States Food and Drug Administration's (FDA)'s approval of an Investigational Device Exemption (IDE). The study will contribute safety data to advance the device as a broad-spectrum countermeasure against bioterror and pandemic threats, including Ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).
About Aethlon Medical, Inc.
Aethlon Medical creates targeted therapeutic devices to address infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. For more information, please visit http://www.aethlonmedical.com/ and connect with the Company on Twitter, LinkedIn, Facebook and Google+.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
Leah-Michelle Nebbia (for interviews requests)
Golin
202-585-2651
lnebbia@golin.com
James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
Logo - http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/...ited-states-300001546.html
SOURCE Aethlon Medical, Inc.
Copyright 2014 PR Newswire
es nervt ,das die aktie nicht in deutschland gehandelt wird :((((